Georgia Medicare Prostate Cancer Screening 2026 Guide

Medicare covers annual prostate cancer screening for eligible male beneficiaries age 50 and older through a benefit established by Section 4103 of the Balanced Budget Act of 1997 (BBA, Public Law 105-33), codified at Section 1861(oo) of the Social Security Act (42 U.S.C. 1395x(oo)), and implemented at 42 CFR 410.39. The benefit became effective January 1, 2000. Two screening modalities are covered: the digital rectal examination (DRE) and the prostate-specific antigen (PSA) blood test. Together these modalities form the core annual screening pathway for prostate cancer in the Medicare population.

For Georgia male Medicare beneficiaries, the prostate cancer screening benefit has particular urgency. African American men face approximately 60 percent higher prostate cancer incidence and more than twice the prostate cancer mortality compared to non-Hispanic white men. Georgia's large African American Medicare male population means systematic prostate cancer screening discussion and shared decision-making is among the highest-impact preventive interactions in clinical practice. The benefit framework is notably different from other Medicare cancer screening benefits because the USPSTF has not adopted prostate cancer screening as Grade A or B, meaning the ACA Section 4104 cost-sharing waiver does not apply to the screening DRE. The PSA blood test is processed under the Medicare Clinical Laboratory Fee Schedule with no beneficiary cost-sharing for the laboratory service. This guide explains the statutory framework, eligibility, modalities, coding, the nuanced cost-sharing structure, USPSTF Grade C-driven shared decision-making, coordination with urology specialty care, and the Georgia urology landscape so beneficiaries, families, and clinicians can navigate the benefit thoughtfully.

By Brevy Care Team

Part 1: The Statutory and Regulatory Framework

Section 1861(oo) of the Social Security Act

Section 1861(oo) of the Social Security Act (42 U.S.C. 1395x(oo)) defines "prostate cancer screening tests" for Medicare coverage purposes. The statute identifies the covered modalities: a digital rectal examination and a prostate-specific antigen blood test. The statute also authorizes the Secretary of Health and Human Services to add other tests or procedures determined to be appropriate for prostate cancer screening through the National Coverage Determination process. To date, CMS has not added additional modalities under this authorization, but the framework permits future expansion if scientific evidence supports it.

Balanced Budget Act of 1997 Section 4103 Origin

The prostate cancer screening benefit was established by Section 4103 of the Balanced Budget Act of 1997 (BBA, Public Law 105-33). President Clinton signed the BBA on August 5, 1997. Unlike most BBA preventive service expansions which took effect on January 1, 1998, the prostate cancer screening benefit had a delayed effective date of January 1, 2000 to allow for regulatory development and CMS implementation.

At the time of the BBA enactment, prostate cancer screening was clinically promising but evidence regarding screening benefits and harms remained evolving. The benefit's creation reflected a congressional decision to provide Medicare coverage for a screening that many male Medicare beneficiaries were already receiving in clinical practice, and to ensure access to PSA testing as the test became increasingly available.

42 CFR 410.39 Implementing Regulations

The implementing regulations for prostate cancer screening are codified at 42 CFR 410.39. The regulations specify:

• The two covered modalities: digital rectal examination and prostate-specific antigen blood test.
• The annual frequency limit.
• The male sex and age 50 eligibility threshold.
• The provider requirements for the DRE.
• The clinical laboratory requirements for the PSA.
• The coordination with diagnostic services when screening results require additional workup.

Related Statutory and Regulatory Authority

Several other Medicare preventive services statutes coordinate with the prostate cancer screening benefit:

• Section 1861(ww) SSA: Initial Preventive Physical Examination (IPPE, Welcome to Medicare visit). Often includes prostate cancer screening discussion.
• Section 1861(hhh) SSA: Annual Wellness Visit (AWV). Includes personalized prevention plan documenting prostate cancer screening status and shared decision-making.
• Section 1861(ddd) SSA: General preventive services framework.
• ACA Section 4104 (Public Law 111-148): Preventive services cost-sharing waiver effective January 1, 2011 (NOT APPLICABLE to prostate cancer screening because USPSTF Grade C/D does not qualify).
• Medicare Clinical Laboratory Fee Schedule: The PSA test is processed under the laboratory fee schedule with separate cost-sharing rules from the Part B physician fee schedule.

USPSTF Recommendation History

The USPSTF prostate cancer screening recommendation has evolved significantly:

• 2008 USPSTF: Grade I (insufficient evidence) for men under age 75, Grade D (recommend against) for men age 75 and older.
• 2012 USPSTF: Grade D (recommend against) for all men regardless of age.
• 2018 USPSTF (current): Grade C (recommend individualized shared decision-making) for men age 55-69, Grade D (recommend against routine screening) for men age 70 and older.

The 2018 update represented a meaningful change from the 2012 Grade D blanket recommendation against screening. The 2018 recommendation acknowledged that some men benefit from screening while others experience overdiagnosis and overtreatment harms, and that the balance should be discussed individually with each patient.

Despite the 2018 update, Grade C does not qualify for the ACA Section 4104 cost-sharing waiver, which applies only to Grade A and Grade B recommendations. As a result, the screening DRE remains subject to standard Part B cost-sharing.

Part 2: Eligible Beneficiaries

Age Eligibility

Male Medicare beneficiaries become eligible for annual prostate cancer screening the day after their 50th birthday. The Medicare statutory eligibility threshold (age 50) is older than the typical age range when prostate cancer first becomes clinically meaningful but younger than the USPSTF shared decision-making age range (55-69).

Sex Eligibility

Prostate cancer screening under Section 1861(oo) is specifically defined as a service for male beneficiaries because the prostate gland is a male reproductive anatomy structure.

Annual Frequency Calculation

The annual frequency limit for DRE under HCPCS G0102 and PSA under HCPCS G0103 is calculated as 11 full months elapsed from the most recent screening. For example, if a beneficiary had a screening DRE on June 15, 2026, the next screening DRE is covered on or after June 1, 2027 (the date 11 full months later, the first day of the month after 11 calendar months elapsed). This is a more permissive frequency calculation than some other Medicare preventive services that calculate the reset more strictly.

Practical Beneficiary Population Considerations

Most Medicare male beneficiaries enroll at age 65, meaning the age 50 eligibility primarily affects men who enroll early through disability eligibility or End-Stage Renal Disease eligibility. For aging-in male beneficiaries enrolling at age 65, the practical screening window aligns approximately with the USPSTF shared decision-making age range (55-69), making the age 65-69 period particularly important for systematic shared decision-making.

The USPSTF Grade D recommendation against routine screening for men age 70 and older creates a practical inflection point: many Medicare male beneficiaries age into the "recommend against" age range during their Medicare enrollment. Shared decision-making discussions about discontinuing screening become important counseling moments.

Part 3: Covered Screening Modalities

Digital Rectal Examination (DRE)

The digital rectal examination is a physical examination of the prostate gland performed by a clinician inserting a gloved, lubricated finger through the rectum to palpate the prostate's posterior surface. The DRE evaluates prostate size, contour, consistency, and the presence of nodules or asymmetry.

Medicare covers the screening DRE annually for male beneficiaries age 50 and older under HCPCS G0102. The DRE can be performed by:

• Primary care physicians.
• Urologists.
• Other qualified physicians.
• Some advanced practice providers under state scope of practice.

The DRE is performed in office-based clinical settings without specialized equipment beyond standard examination supplies. The examination typically takes less than 1 minute.

Prostate-Specific Antigen (PSA) Blood Test

The PSA blood test measures the concentration of prostate-specific antigen, a glycoprotein produced by prostate cells, in the blood. Elevated PSA is associated with prostate cancer but is not specific to cancer: benign prostatic hyperplasia (BPH), prostatitis, recent ejaculation, recent DRE, and urinary retention can all elevate PSA.

Medicare covers the screening PSA test annually for male beneficiaries age 50 and older under HCPCS G0103. The test requires a blood draw, processing by a certified clinical laboratory, and reporting of results.

PSA results are typically reported as ng/mL (nanograms per milliliter). Common PSA result ranges and their clinical significance vary:

• PSA less than 4.0 ng/mL: Traditional cutoff for "normal," though no PSA level guarantees absence of prostate cancer.
• PSA 4.0 to 10.0 ng/mL: Intermediate range with higher cancer risk; many men in this range undergo additional workup.
• PSA greater than 10.0 ng/mL: Substantially elevated cancer risk; urology referral and diagnostic workup typical.

The interpretation of PSA is increasingly nuanced beyond absolute cutoffs. PSA density (PSA divided by prostate volume), PSA velocity (rate of change over time), free PSA percentage (ratio of unbound to total PSA), and prostate health index (PHI) are increasingly used in modern practice to refine cancer risk assessment.

Coverage Code Summary

Part 4: Cost-Sharing Structure

Why Cost-Sharing Differs From Most Preventive Services

Most Medicare preventive services aligned with USPSTF Grade A or B recommendations receive the ACA Section 4104 cost-sharing waiver, meaning beneficiaries pay $0 for the screening service. Prostate cancer screening is different because USPSTF has graded prostate cancer screening Grade C (for age 55-69) and Grade D (for age 70+), and Grade C/D recommendations do not qualify for the ACA Section 4104 waiver.

This cost-sharing distinction is one of the most important counseling points for prostate cancer screening because beneficiaries may expect $0 cost-sharing based on their experience with cardiovascular disease screening, diabetes screening, mammography, and colorectal cancer screening, all of which are USPSTF-aligned and ACA-waived.

DRE Cost-Sharing Under HCPCS G0102

The screening DRE under HCPCS G0102 is subject to standard Part B cost-sharing:

• Part B deductible ($240 in 2024, adjusted annually).
• 20 percent coinsurance after deductible.

The Medicare-allowed amount for HCPCS G0102 is modest (typically under $20), so the practical out-of-pocket cost for the DRE is small. However, when the DRE is performed during the same visit as other services, the visit-level cost-sharing may include the DRE as one of multiple billed services.

PSA Cost-Sharing Under HCPCS G0103

The screening PSA test under HCPCS G0103 is processed under the Medicare Clinical Laboratory Fee Schedule rather than the Part B Physician Fee Schedule. Laboratory services under the Clinical Laboratory Fee Schedule have a different cost-sharing rule:

• Beneficiary cost-sharing for clinical laboratory services is $0 because the Clinical Laboratory Fee Schedule does not apply deductible or coinsurance to laboratory services.

This means the PSA blood test itself is effectively free to the beneficiary, even though the broader prostate cancer screening benefit is not ACA Section 4104 waived. The DRE remains subject to standard Part B cost-sharing, but the PSA blood test (which is the more clinically informative modality in current practice) is $0 to the beneficiary.

Diagnostic PSA Versus Screening PSA

When PSA is performed for diagnostic reasons (evaluation of symptoms, follow-up of an abnormal screening, monitoring known prostate cancer), it is billed under different CPT codes (84153 for total PSA, 84154 for free PSA) rather than HCPCS G0103. Diagnostic PSA may be subject to standard Clinical Laboratory Fee Schedule rules ($0 to beneficiary) or may be considered part of a different service depending on context.

Cost-Sharing for Abnormal Screening Follow-Up

When the screening DRE or PSA identifies findings requiring additional workup, the beneficiary enters a diagnostic pathway with different cost-sharing. Diagnostic services typically include:

• Urology consultation: Subject to standard Part B cost-sharing (deductible plus 20% coinsurance).
• Multiparametric prostate MRI: Subject to standard Part B cost-sharing.
• Prostate biopsy: Subject to standard Part B cost-sharing.
• Repeat PSA testing: Processed under Clinical Laboratory Fee Schedule ($0).

Beneficiaries with abnormal screening results should be counseled that the diagnostic workup will involve cost-sharing distinct from the screening itself.

Part 5: USPSTF Grade C and Shared Decision-Making

USPSTF 2018 Recommendation Detail

The USPSTF 2018 update provided Grade C for men age 55-69 with the following language: "For men aged 55 to 69 years, the decision to undergo periodic PSA-based screening for prostate cancer should be an individual one. Before deciding whether to be screened, men should have an opportunity to discuss the potential benefits and harms of screening with their clinician and to incorporate their values and preferences in the decision."

For men age 70 and older, the USPSTF assigned Grade D: "The USPSTF recommends against PSA-based screening for prostate cancer in men 70 years and older."

Benefits of Screening (per USPSTF and AUA Evidence Synthesis)

Potential benefits of prostate cancer screening identified by USPSTF and the American Urological Association include:

• Reduction in prostate cancer mortality: Modest absolute reduction in long-term prostate cancer death over 10-15 years of follow-up.
• Detection of clinically significant cancers: Earlier-stage detection allowing curative treatment.
• Reduction in metastatic disease: Reduction in incidence of metastatic prostate cancer at diagnosis.

Harms of Screening (per USPSTF and AUA Evidence Synthesis)

Potential harms identified include:

• Overdiagnosis: Detection of indolent cancers that would never have caused symptoms or death.
• Overtreatment: Treatment of indolent cancers leading to treatment complications without survival benefit.
• Treatment complications: Urinary incontinence, erectile dysfunction, bowel dysfunction following prostatectomy or radiation.
• Biopsy complications: Bleeding, infection, urinary retention following prostate biopsy.
• Anxiety and decisional regret: Psychological burden of false-positive results and treatment decisions.

Active Surveillance: A Mitigation Strategy

The modern clinical approach to localized low-risk prostate cancer increasingly uses active surveillance rather than immediate definitive treatment. Active surveillance involves close monitoring (serial PSA, periodic prostate MRI, repeat biopsy at intervals) with treatment reserved for evidence of progression. Active surveillance substantially reduces overtreatment harms while preserving the option for treatment of progressive disease.

The growing acceptance of active surveillance has shifted the harm-benefit calculus of screening over the past decade. The USPSTF 2018 Grade C update partially reflected this shift.

Practical Shared Decision-Making in Georgia

Shared decision-making conversations for prostate cancer screening typically address:

1. Family history: First-degree relative with prostate cancer increases risk substantially.
2. Race: African American men face elevated incidence and mortality.
3. Life expectancy: Men with limited life expectancy (less than 10-15 years) are less likely to benefit.
4. Personal preference: Some men prefer to know; others prefer to avoid potential overdiagnosis.
5. Treatment preferences: Active surveillance availability versus immediate treatment preference.

In Georgia, the elevated African American disease burden makes shared decision-making particularly important. African American men age 55-69 typically benefit from explicit screening discussion given their elevated baseline risk.

Part 6: African American Disease Burden in Georgia

Incidence and Mortality Statistics

African American men face approximately 60 percent higher prostate cancer incidence and more than twice the prostate cancer mortality compared to non-Hispanic white men nationally. In Georgia, where the African American population is substantial, these disparities translate into a major public health burden for the African American male Medicare population.

The Georgia Comprehensive Cancer Registry consistently documents elevated prostate cancer mortality particularly in African American men and in rural counties with high African American populations. The Black Belt region of south and southwest Georgia includes counties with the highest age-adjusted prostate cancer mortality rates in the state.

Contributing Factors

Multiple factors contribute to the African American prostate cancer disparity:

• Biological factors: Higher rates of aggressive prostate cancer subtypes and earlier age at presentation.
• Genetic factors: Possible differences in germline genetic variants influencing prostate cancer risk and aggressiveness.
• Access factors: Lower screening uptake, later-stage diagnosis at presentation, treatment access disparities.
• Socioeconomic factors: Insurance, education, and income disparities affecting care access and quality.
• Historical health system factors: Persistent trust and access issues with mainstream health care.

Screening Implications

The elevated disease burden in African American men provides clinical justification for proactive shared decision-making discussions starting earlier than the general USPSTF age 55 trigger. Many guidelines from the American Cancer Society, American Urological Association, and National Comprehensive Cancer Network recommend that African American men consider screening discussions beginning at age 45, recognizing the elevated incidence and earlier onset of aggressive disease.

In Georgia, the practical implication is that African American Medicare male beneficiaries enrolled before age 50 through disability or ESRD eligibility may benefit from shared decision-making discussions, even though Medicare coverage begins only at age 50.

Part 7: Coordination With Urology Specialty Care

Indications for Urology Referral

Beneficiaries with abnormal screening results require urology specialty referral for diagnostic evaluation. Typical referral triggers include:

• PSA greater than 4.0 ng/mL (with adjustments for age, race, and other factors).
• Abnormal DRE findings (nodule, asymmetry, induration).
• Rapidly rising PSA velocity over serial measurements.
• Family history of prostate cancer with elevated PSA in the intermediate range.

Diagnostic Workup Options

Modern prostate cancer diagnostic workup increasingly uses:

1. Repeat PSA testing: Confirms PSA elevation and assesses velocity.
2. PSA derivatives: Free PSA percentage, PSA density, prostate health index (PHI).
3. Multiparametric prostate MRI: Identifies suspicious lesions for targeted biopsy and assigns Prostate Imaging Reporting and Data System (PI-RADS) scores.
4. Prostate biopsy: Histologic confirmation through transrectal ultrasound-guided or MRI-targeted biopsy. Gleason grading determines aggressiveness.
5. Genomic testing: Specific contexts (Decipher, Prolaris, Oncotype DX prostate) to refine treatment decisions.

Multiparametric Prostate MRI Pre-Biopsy Pathway

The pre-biopsy multiparametric prostate MRI has become increasingly important in modern practice. MRI before biopsy can:

• Identify suspicious lesions amenable to targeted biopsy.
• Allow some men with negative MRI to avoid biopsy.
• Improve detection of clinically significant cancer while reducing detection of indolent cancer.

Multiparametric prostate MRI is covered by Medicare when medically necessary following abnormal screening. It is subject to standard Part B cost-sharing.

Treatment Pathways

When prostate cancer is diagnosed, treatment options depend on disease characteristics:

• Active surveillance: Close monitoring for low-risk disease.
• Radical prostatectomy: Surgical removal of the prostate (open, laparoscopic, or robot-assisted).
• External beam radiation therapy: Modern intensity-modulated or stereotactic body radiation therapy.
• Brachytherapy: Internal radiation through implanted seeds.
• Androgen deprivation therapy: For higher-risk or advanced disease.
• Combined modality therapy: For higher-risk localized or locally advanced disease.

Part 8: The Major Georgia Urology Landscape

Atlanta Metropolitan Area

The Atlanta metropolitan area has extensive urology capacity:

• Emory Urology: Academic urology at Emory University with comprehensive clinical and surgical services.
• Wellstar Urology: Network-wide urology coverage across the north and west Atlanta metropolitan area.
• Piedmont Urology: Piedmont Healthcare urology with multiple locations.
• Northside Hospital Urology: Urology services particularly strong in north Atlanta.
• Georgia Urology PA: Large independent urology group with multiple locations throughout metropolitan Atlanta and surrounding counties.
• Emory Winship Cancer Institute: Comprehensive cancer center for advanced prostate cancer care.

Augusta and East Georgia

Augusta University Urology serves east Georgia with academic urology and surgical services. The Georgia Cancer Center at Augusta University provides integrated cancer care.

Macon and Central Georgia

Atrium Health Navicent (Macon) and Coliseum Medical Centers provide urology services for central Georgia. Houston Healthcare in Warner Robins also offers urology coverage.

Savannah and Coastal Georgia

Memorial Health (Savannah) and St. Joseph's Candler Health System provide urology services for coastal Georgia.

Albany and Southwest Georgia

Phoebe Putney Memorial Hospital (Albany) is the primary urology resource for southwest Georgia. The catchment includes Dougherty, Lee, Worth, Mitchell, Baker, Calhoun, and surrounding counties.

Athens and Northeast Georgia

Piedmont Athens Regional and St. Mary's Health Care System provide urology services for the Athens area and northeast Georgia.

Rural Georgia Access

Many rural Georgia counties lack local urology providers. Beneficiaries in counties without local urology access typically travel to regional medical centers for urology consultation, prostate MRI, and prostate biopsy. This geographic constraint is particularly significant given that African American men in rural Black Belt counties face both elevated disease risk AND constrained specialty access.

Part 9: Coordination With Other Medicare Preventive Services

Coordination With the Annual Wellness Visit

The Annual Wellness Visit (AWV), authorized by Section 1861(hhh) of the Social Security Act, includes a personalized prevention plan that documents preventive services status and recommendations. Prostate cancer screening is a routine AWV component for male beneficiaries:

• Documentation of most recent DRE and PSA dates and results.
• Family history risk assessment.
• Race-specific risk discussion (particularly important for African American men).
• Shared decision-making discussion based on USPSTF Grade C/D framework.
• Referral for screening when appropriate.

Coordination With the Initial Preventive Physical Examination

The Initial Preventive Physical Examination (IPPE) authorized by Section 1861(ww) is the one-time preventive visit available within the first 12 months of Part B enrollment. The IPPE includes assessment of preventive services needs including initial shared decision-making about prostate cancer screening for male beneficiaries.

Coordination With Other Cancer Screening

Many male Medicare beneficiaries receive coordinated cancer screening, including colorectal cancer (Section 1861(pp)) and prostate cancer, through the same primary care visit cycle. The AWV serves as the natural coordinating visit for these multiple screening discussions.

Part 10: Worked Examples

Worked Example 1: Atlanta African American Age 60 PSA + DRE Annual Screening

Beneficiary: 60-year-old African American man in Fulton County, no family history, no symptoms, last screening 12 months ago.

He receives his AWV at Grady Health System. His primary care physician documents the elevated African American prostate cancer risk and the importance of shared decision-making. The beneficiary expresses preference to continue annual screening given his family awareness of the disparity. The physician orders the annual DRE and PSA.

Procedure: DRE performed at the visit (HCPCS G0102). Result: smooth prostate, no nodules. PSA blood draw sent to clinical laboratory (HCPCS G0103). PSA result: 2.8 ng/mL (below 4.0 threshold).

Billing: G0102 subject to standard Part B cost-sharing (Part B deductible if not yet met plus 20% coinsurance on the approximately $15 allowed amount, minimal practical cost). G0103 processed under Clinical Laboratory Fee Schedule with $0 to beneficiary. Next annual screening covered on or after 11 months later.

Worked Example 2: Rural Southwest Georgia Primary Care PSA Testing

Beneficiary: 67-year-old man in Worth County, no family history, no urology specialist locally.

The beneficiary's primary care physician at the Worth County FQHC performs annual prostate cancer screening discussion as part of the AWV. The beneficiary opts to continue annual PSA testing and accepts the DRE.

Procedure: DRE in office (G0102). Result: mildly enlarged prostate consistent with benign prostatic hyperplasia, no suspicious nodules. PSA blood draw sent to LabCorp (G0103). Result: 6.2 ng/mL (elevated).

Billing: G0102 standard Part B cost-sharing. G0103 $0.

The elevated PSA triggers a discussion about urology referral. The nearest urologist is at Phoebe Putney in Albany, 30 miles away. The beneficiary schedules urology consultation. Phoebe Putney urology orders multiparametric prostate MRI as the modern pre-biopsy approach. The MRI is subject to standard Part B cost-sharing.

Worked Example 3: Family History High-Risk Earlier Screening Discussion

Beneficiary: 52-year-old man in Cobb County, father diagnosed with prostate cancer at age 58, brother diagnosed at age 56.

Strong family history substantially elevates the beneficiary's risk. His primary care physician at Wellstar discusses screening at his AWV. The USPSTF Grade C framework supports earlier screening for higher-risk men, and family history is a key risk factor.

Procedure: DRE performed (G0102). Result: normal. PSA blood draw (G0103). Result: 1.9 ng/mL (within normal range).

Billing: G0102 standard Part B cost-sharing. G0103 $0.

The beneficiary is scheduled for continued annual screening with consideration of more intensive monitoring if PSA velocity increases. He is also offered genetic counseling discussion given the strong family history possibly suggestive of BRCA-related or other hereditary cancer syndrome.

Worked Example 4: Abnormal PSA Referral to Urologist for Prostate Biopsy

Beneficiary: 65-year-old man in Cherokee County, prior PSA 3.2 ng/mL, current annual screening shows PSA 5.8 ng/mL (rising).

The PSA velocity and elevated absolute value prompt urology referral. His primary care physician at Piedmont refers him to Piedmont Urology.

Piedmont Urology orders confirmatory PSA in 6 weeks (LabCorp), free PSA percentage (typically also processed under Clinical Laboratory Fee Schedule), and multiparametric prostate MRI. Confirmatory PSA is 6.1 ng/mL. Free PSA is 12% (lower percentages suggest higher cancer risk). MRI shows a PI-RADS 4 lesion in the left peripheral zone.

The urologist recommends MRI-targeted prostate biopsy. The biopsy is performed at Piedmont with conscious sedation. Pathology shows Gleason 3+4=7 prostate cancer (intermediate risk).

Billing: Original screening DRE and PSA per usual rules. Subsequent confirmatory PSA processed under Clinical Laboratory Fee Schedule ($0). MRI subject to standard Part B cost-sharing. Biopsy subject to standard Part B cost-sharing.

Treatment options discussed: active surveillance, radical prostatectomy, external beam radiation, brachytherapy. The beneficiary elects to consult with both urology and radiation oncology to inform his decision.

Worked Example 5: Age 72 Shared Decision-Making to Discontinue Screening

Beneficiary: 72-year-old man in Gwinnett County, multiple comorbidities (diabetes, CKD stage 3, congestive heart failure), life expectancy estimated less than 10 years.

USPSTF Grade D recommends against routine screening for men age 70 and older. The combination of age plus limited life expectancy makes overdiagnosis and overtreatment particularly likely to cause harm without offsetting survival benefit.

His primary care physician at Northside discusses discontinuation of routine prostate cancer screening at his AWV. The beneficiary, having received annual screening for many years, expresses surprise at the recommendation. The physician explains the harm-benefit shift at advanced age with limited life expectancy.

After discussion, the beneficiary elects to discontinue routine screening but understands that diagnostic PSA can be obtained if symptoms develop (urinary obstruction, bone pain, weight loss).

Documentation: AWV personalized prevention plan documents shared decision-making, beneficiary informed of USPSTF Grade D, decision to discontinue routine screening.

Worked Example 6: Multiparametric Prostate MRI Before Biopsy Decision

Beneficiary: 62-year-old man in DeKalb County, PSA 4.8 ng/mL, DRE normal.

His primary care physician at Emory refers him to Emory Urology. The urologist orders multiparametric prostate MRI before deciding on biopsy.

MRI result: PI-RADS 2 (low probability of clinically significant cancer) with no suspicious lesions. The urologist discusses with the beneficiary the option to defer biopsy and continue active monitoring with serial PSA.

The beneficiary elects active monitoring. He returns in 6 months for repeat PSA. PSA at 6 months is 4.5 ng/mL (stable). He is scheduled for annual MRI surveillance in 12 months.

This example illustrates the modern pathway in which multiparametric prostate MRI can spare some men from biopsy and avoid the harms of detecting indolent disease.

Billing: PSA per usual ($0). MRI subject to standard Part B cost-sharing.

Part 11: Best Practices

Best Practice 1: Document Race and Family History Carefully

Race (particularly African American) and family history (especially first-degree relative with prostate cancer) substantially elevate risk and inform shared decision-making. Carefully documenting these factors supports appropriate discussion.

Best Practice 2: Conduct Genuine Shared Decision-Making

USPSTF Grade C requires individualized shared decision-making. Generic discussion ("would you like a PSA test?") does not satisfy the shared decision-making standard. Discussion should cover benefits, harms, beneficiary preferences, and life expectancy considerations.

Best Practice 3: Use the AWV as the Coordinating Visit

The AWV is the natural coordinating visit for prostate cancer screening discussion, family history documentation, and ordering. Many practices integrate prostate cancer screening shared decision-making into the AWV workflow.

Best Practice 4: Counsel on Cost-Sharing Distinction

Beneficiaries are often surprised that the DRE has standard Part B cost-sharing (unlike most other screening). Pre-visit counseling addresses expectations.

Best Practice 5: Recognize the Age 70 Inflection Point

USPSTF Grade D for men age 70 and older creates a natural inflection point for shared decision-making about screening discontinuation. The AWV is the appropriate venue for this conversation.

Best Practice 6: Coordinate With Urology for Abnormal Results

Abnormal screening results require timely urology referral. Streamlined referral pathways from primary care to urology consultation, multiparametric MRI, and biopsy support optimal diagnostic workup.

Best Practice 7: Consider Multiparametric Prostate MRI Before Biopsy

Modern prostate cancer diagnostic workup increasingly uses pre-biopsy multiparametric MRI to inform biopsy decision. This pathway reduces unnecessary biopsies and improves detection of clinically significant cancer.

Best Practice 8: Discuss Active Surveillance for Low-Risk Disease

Active surveillance is appropriate management for many low-risk prostate cancers and substantially reduces overtreatment harms. Beneficiaries diagnosed with low-risk disease should be informed of active surveillance as an option.

Best Practice 9: Engage African American Men Proactively

African American men face substantially elevated risk. Proactive shared decision-making engagement starting earlier (potentially age 45 in clinical practice) supports informed choices for this high-risk population.

Best Practice 10: Assess Life Expectancy for Older Beneficiaries

Beneficiaries with limited life expectancy (less than 10 years) generally do not benefit from prostate cancer screening because indolent cancers may never become clinically meaningful. Life expectancy assessment supports thoughtful screening recommendations.

Best Practice 11: Document Shared Decision-Making in the Medical Record

Shared decision-making documentation in the AWV personalized prevention plan supports continuity, quality measures, and demonstrates appropriate clinical workflow.

Best Practice 12: Address PSA Test Pre-Analytical Factors

PSA can be elevated by recent ejaculation, recent DRE, urinary retention, prostatitis, and other factors. Counseling beneficiaries on pre-test factors (avoid ejaculation 48 hours before blood draw, draw blood before DRE) improves test interpretability.

Best Practice 13: Coordinate With Genetic Counseling for Strong Family Histories

Beneficiaries with strong family histories of prostate cancer and other cancers (particularly BRCA-related cancers including breast, ovarian, pancreatic) may benefit from genetic counseling and germline testing.

Best Practice 14: Educate on Active Surveillance Versus Treatment Tradeoffs

Beneficiaries facing treatment decisions need balanced information about active surveillance versus immediate definitive treatment. Multidisciplinary consultation with urology, radiation oncology, and medical oncology supports informed decisions.

Part 12: Common Issues

Common Issue 1: Cost-Sharing Surprise on DRE

Beneficiaries who expect $0 cost-sharing (based on experience with ACA-waived screening) are sometimes surprised by Part B cost-sharing on the DRE. Pre-visit counseling addresses expectations.

Common Issue 2: Inadequate Shared Decision-Making

USPSTF Grade C requires individualized discussion, but real-world practice sometimes substitutes brief "do you want PSA?" questions for substantive shared decision-making. Improving the quality of these discussions is an ongoing practice challenge.

Common Issue 3: PSA Test Pre-Analytical Variability

PSA results can be confounded by recent ejaculation, recent DRE, prostatitis, and other factors. Beneficiaries who do not understand pre-analytical factors may have inflated PSA results triggering unnecessary workup.

Common Issue 4: Failure to Discuss Age 70 Discontinuation

Many men age 70 and older continue routine annual screening despite USPSTF Grade D recommendation against. Failure to engage in shared decision-making at the age 70 transition produces continued screening that may not benefit and may harm.

Common Issue 5: Family History Underdocumentation

Family history documentation in primary care records is often incomplete. Without accurate family history, risk-stratified shared decision-making is undermined.

Common Issue 6: African American Risk Underrecognition

Despite published evidence of substantial elevated risk, African American men's screening risk profile is not always discussed proactively. This represents a missed opportunity for risk-informed shared decision-making.

Common Issue 7: Confusion Between Screening and Diagnostic PSA

Beneficiaries with symptoms or following abnormal screening sometimes have their PSA ordered as "screening" (G0103) when it should be ordered as diagnostic (CPT 84153). Misclassification can affect billing.

Common Issue 8: Skipping Multiparametric MRI

Some referral pathways still proceed directly to biopsy without pre-biopsy multiparametric MRI. Modern best practice favors MRI before biopsy in most contexts.

Common Issue 9: Inadequate Active Surveillance Counseling

Newly diagnosed low-risk prostate cancer patients sometimes proceed to definitive treatment without adequate active surveillance counseling. Active surveillance may be more appropriate for many men.

Common Issue 10: Provider Network Constraints in Medicare Advantage

Medicare Advantage plans may have urology network constraints affecting where beneficiaries can receive consultation, MRI, and biopsy. Out-of-network use can produce higher cost-sharing.

Common Issue 11: Rural Access Barriers

Rural Georgia beneficiaries face urology access challenges that delay diagnostic workup after abnormal screening. Coordinating referrals to regional urology centers and providing transportation assistance supports timely diagnosis.

Common Issue 12: Insufficient Pre-Test Counseling on Harms

Beneficiaries sometimes consent to screening without adequate counseling on potential harms (overdiagnosis, overtreatment, biopsy complications). Pre-test counseling supports informed consent.

Common Issue 13: Documentation Gaps After Outside Procedures

When beneficiaries undergo prostate biopsy or treatment at outside facilities, the procedure and findings may not be communicated back to the primary care record. This produces continuity gaps.

Common Issue 14: Underutilization of Genetic Counseling

Beneficiaries with strong family histories suggestive of BRCA mutations or other hereditary cancer syndromes are sometimes managed with standard screening rather than appropriate genetic evaluation. BRCA mutations affect prostate cancer risk and inform treatment decisions.

Contacts and Resources

1. Medicare: 1-800-MEDICARE (1-800-633-4227) for general Medicare questions and coverage.
2. Palmetto GBA Medicare Administrative Contractor: 1-866-238-9650 for Medicare claims and coverage in Georgia.
3. Georgia Department of Community Health Member Services: 1-866-211-0950 for Georgia Medicaid coordination.
4. GeorgiaCares SHIP: 1-866-552-4464 for free Medicare counseling.
5. Medicare Rights Center: 1-800-333-4114 for Medicare advocacy and assistance.
6. Atlanta Legal Aid: 404-377-0701 for legal assistance with Medicare issues.
7. Georgia Legal Services Program: 1-800-498-9469 for legal assistance outside metropolitan Atlanta.
8. 211 Georgia: Dial 211 for community resource referrals.
9. Eldercare Locator: 1-800-677-1116 for connection to local aging services.
10. Georgia Department of Public Health: 404-657-2700 for state public health resources.
11. American Cancer Society: 1-800-227-2345 for cancer information, support, and resources.
12. Prostate Cancer Foundation: 1-800-757-2873 for prostate cancer-specific information and patient support.
13. ZERO Prostate Cancer: 1-888-245-9455 for prostate cancer advocacy and support.
14. American Urological Association: 410-689-3700 for professional urology information.
15. Emory Urology: Academic urology services in Atlanta.
16. Wellstar Urology: Network urology in north and west Georgia.
17. Georgia Urology PA: Large independent urology group across metropolitan Atlanta.
18. Acentra Health QIO: 1-844-455-8708 for Medicare quality of care concerns.

Find personalized help understanding your Medicare prostate cancer screening coverage in Georgia at brevy.com.